FAPI PET for Lung Fibrosis

Recruiting Early Phase 1 Interventional Study
Interstitial Lung Disease Idiopathic Interstitial Pneumonias Drug-Induced Pneumonitis Hypersensitivity Pneumonitis Radiation Pneumonitis Pneumoconiosis Pulmonary Fibrosis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Diagnostic
Participants needed
30 (estimated)
Sponsor
University of California, Los Angeles · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in normal and fibrotic lung tissues of patients with interstitial lung disease. The study will include patients with interstitial lung disease who have or will initiate a n…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria * Patients with ILD confirmed by CT at time of staging * Patients who have initiated or will initiate a new ILD medication with 3 months of enrollment OR Patients who are scheduled to undergo tissue biopsy or surgery of the lung * Patients are ≥ 18 years old at the time of the ra…
Contacts

Stephanie Lira

3102067372

StephanieLira@mednet.ucla.edu

CONTACT

Contreras M Maria, BS

3102067372

MMContreras@mednet.ucla.edu

CONTACT